Followers | 88 |
Posts | 8196 |
Boards Moderated | 0 |
Alias Born | 06/17/2013 |
![](https://investorshub.advfn.com/uicon/404071.png?cb=1506674193)
Tuesday, March 19, 2019 12:20:52 PM
NanoStilbene Shown to Reduce Tumor Necrosis Factor-a (TNF-a )
in Cancer Patients
http://ih.advfn.com/stock-market/USOTC/therapeutic-solutions-international-inc-pc-TSOI/stock-news/79295986/therapeutic-solutions-international-continues-to-r
OCEANSIDE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Therapeutics Solutions International, Inc., (USOTC: TSOI) announced today further refinement of their patented formulation of nanoparticle pterostilbene known as NanoStilbene™.
NanoStilbene™ is a nanoemulsion of nanoparticle pterostilbene in the 75-90nm (nanometer) range at a concentration of 200mg per milliliter. We have successfully produced the same stable nanoemulsion using peach kernel extract to fortify the NanoStilbene against tumor necrosis factor-a (TNF-a ).
“We recently announced the conclusion of a clinical trial involving 12 advanced, solid tumor, cancer patients who received the equivalence of 300mg’s of nanoparticle pterostilbene daily for three weeks which showed on average a 26% decrease in TNF-a 1,” said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. “By adding peach kernel extract to our nanoemulsion formulation we intend to fortify NanoStilbene to be even more effective against high levels of inflammatory cytokines.”
“In a recent paper, peach kernel extract has been shown to reduce tissue factor (TF) elevations in atherosclerosis, which is a pathological process in arteries due to plaque formation, by first reducing tumor necrosis factor-a (TNF-a)2,” said Dr. Thomas Ichim, Director of Therapeutic Solutions International. “Tumor necrosis factor (TNF) is a type of messenger protein known as a cytokine that is produced by white blood cells. It promotes inflammation, produces other cells used in the inflammatory response, and can help cells heal” added Dr. Ichim.
“By adding the peach kernel extract to the nanoemulsion formulation, our purpose is to open the way for new therapeutic approaches that might eventually decrease the prevalence of tumor necrosis factor-a (TNF-a) in not only cancer patients where TNF-a has been shown to play a key role in these inflammatory processes but also in acute and chronic inflammatory conditions such as trauma, sepsis, infection, rheumatoid arthritis, atherosclerosis, and cardiovascular disease” said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International.
TNF-a is a member of a growing family of peptide mediators comprising at least 19 cytokines, including lymphotoxin-, Fas ligand, and CD40 ligand. TNF-a has important proinflammatory properties, which play crucial roles in the innate and adaptive immunity, cell proliferation, and apoptotic processes. The cytokine is produced by different kind of cells, including macrophages, monocytes, T-cells, smooth muscle cells, adipocytes, and fibroblasts.
Recent TSOI News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:51:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 04:47:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:46:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 12:44:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/30/2024 06:46:26 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 04:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 10:03:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:15:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 07:12:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 10:25:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 11:16:15 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/08/2024 05:15:25 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/06/2024 11:34:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 08:42:55 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/17/2024 11:15:01 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/04/2024 09:03:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 07:44:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 05:39:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:17:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 11:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 06:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 05:44:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:24:52 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 11:10:01 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM